Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: Consortium for improving survival of lymphoma (CISL) study

Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Dok Hyun Yoon, Deok Hwan Yang, Won Sik Lee, Hyo Jung Kim, Ho Young Yhim, Seong Hyun Jeong, Jong Ho Won, Suee Lee, Jee Hyun Kong, Sung Nam Lim, Jun Ho Ji, Kyung A. Kwon, Gyeong Won Lee, Jae Hoon Lee, Ho Sup Lee, Ho Jin ShinCheolwon Suh

Research output: Contribution to journalArticle

Abstract

Background: The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending the period of remission in MZL patients remains an essential goal. This multicenter, single-arm, open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP (rituximab, cyclophosphamide, vincristine, and prednisolone). The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further investigation. Methods: Prior to rituximab-maintenance therapy, patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV MZL. Rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), and vincristine (1.4 mg/m2; maximum 2 mg) were administered via an intravenous infusion on day 1 of each 3-week cycle, while oral prednisolone (100 mg) was given on days 1-5 of each 3-week cycle. The patients who achieved complete response (CR), partial response (PR), or stable disease (SD) to R-CVP treatment, were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m2 every 8 weeks for up to 12 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and treatment safety. Results: 47 patients were enrolled, of whom, 45 (96%) received rituximab-maintenance treatment. Fifteen (33%) patients had nodal MZL. Following R-CVP first-line therapy, 20 (44%), 22 (49%), and 3 (7%) patients achieved CR, PR, and SD, respectively. After a median follow-up of 38.2 months, their observed 3-year PFS rate was 81%. During the rituximab-maintenance, 6 PR and 1 SD patients achieved CR following the administration of R-CVP. Elevated LDH and the presence of B symptoms were found to be significant prognostic factors for PFS (P = 0.003) and demonstrated a 3-year OS rate of 90%. Rituximab-maintenance therapy was well tolerated, and the common treatment-emergent adverse events were sensory neuropathy (18%), myalgia (13%), fatigue (9%), and neutropenia (9%). Conclusion: Rituximab-maintenance therapy following first-line R-CVP demonstrated good PFS in patients with stage III-IV MZL, in addition to a favorable toxicity profile. Trial registration clinicaltrials.gov: NCT01213095

Original languageEnglish
Article number58
JournalCancer Communications
Volume39
Issue number1
DOIs
Publication statusPublished - 2019 Oct 16

Fingerprint

Vincristine
Prednisolone
Cyclophosphamide
Lymphoma
Survival
Therapeutics
Disease-Free Survival
Rituximab
Survival Rate
Maintenance
Myalgia
Neutropenia
Intravenous Infusions

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Oh, Sung Yong ; Kim, Won Seog ; Kim, Jin Seok ; Kim, Seok Jin ; Yoon, Dok Hyun ; Yang, Deok Hwan ; Lee, Won Sik ; Kim, Hyo Jung ; Yhim, Ho Young ; Jeong, Seong Hyun ; Won, Jong Ho ; Lee, Suee ; Kong, Jee Hyun ; Lim, Sung Nam ; Ji, Jun Ho ; Kwon, Kyung A. ; Lee, Gyeong Won ; Lee, Jae Hoon ; Lee, Ho Sup ; Shin, Ho Jin ; Suh, Cheolwon. / Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma : Consortium for improving survival of lymphoma (CISL) study. In: Cancer Communications. 2019 ; Vol. 39, No. 1.
@article{d13f7442acb14c8aab6e66624d5e1a9e,
title = "Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: Consortium for improving survival of lymphoma (CISL) study",
abstract = "Background: The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending the period of remission in MZL patients remains an essential goal. This multicenter, single-arm, open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP (rituximab, cyclophosphamide, vincristine, and prednisolone). The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further investigation. Methods: Prior to rituximab-maintenance therapy, patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV MZL. Rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), and vincristine (1.4 mg/m2; maximum 2 mg) were administered via an intravenous infusion on day 1 of each 3-week cycle, while oral prednisolone (100 mg) was given on days 1-5 of each 3-week cycle. The patients who achieved complete response (CR), partial response (PR), or stable disease (SD) to R-CVP treatment, were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m2 every 8 weeks for up to 12 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and treatment safety. Results: 47 patients were enrolled, of whom, 45 (96{\%}) received rituximab-maintenance treatment. Fifteen (33{\%}) patients had nodal MZL. Following R-CVP first-line therapy, 20 (44{\%}), 22 (49{\%}), and 3 (7{\%}) patients achieved CR, PR, and SD, respectively. After a median follow-up of 38.2 months, their observed 3-year PFS rate was 81{\%}. During the rituximab-maintenance, 6 PR and 1 SD patients achieved CR following the administration of R-CVP. Elevated LDH and the presence of B symptoms were found to be significant prognostic factors for PFS (P = 0.003) and demonstrated a 3-year OS rate of 90{\%}. Rituximab-maintenance therapy was well tolerated, and the common treatment-emergent adverse events were sensory neuropathy (18{\%}), myalgia (13{\%}), fatigue (9{\%}), and neutropenia (9{\%}). Conclusion: Rituximab-maintenance therapy following first-line R-CVP demonstrated good PFS in patients with stage III-IV MZL, in addition to a favorable toxicity profile. Trial registration clinicaltrials.gov: NCT01213095",
author = "Oh, {Sung Yong} and Kim, {Won Seog} and Kim, {Jin Seok} and Kim, {Seok Jin} and Yoon, {Dok Hyun} and Yang, {Deok Hwan} and Lee, {Won Sik} and Kim, {Hyo Jung} and Yhim, {Ho Young} and Jeong, {Seong Hyun} and Won, {Jong Ho} and Suee Lee and Kong, {Jee Hyun} and Lim, {Sung Nam} and Ji, {Jun Ho} and Kwon, {Kyung A.} and Lee, {Gyeong Won} and Lee, {Jae Hoon} and Lee, {Ho Sup} and Shin, {Ho Jin} and Cheolwon Suh",
year = "2019",
month = "10",
day = "16",
doi = "10.1186/s40880-019-0403-7",
language = "English",
volume = "39",
journal = "Cancer Communications",
issn = "1000-467X",
publisher = "BioMed Central Ltd.",
number = "1",

}

Oh, SY, Kim, WS, Kim, JS, Kim, SJ, Yoon, DH, Yang, DH, Lee, WS, Kim, HJ, Yhim, HY, Jeong, SH, Won, JH, Lee, S, Kong, JH, Lim, SN, Ji, JH, Kwon, KA, Lee, GW, Lee, JH, Lee, HS, Shin, HJ & Suh, C 2019, 'Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: Consortium for improving survival of lymphoma (CISL) study', Cancer Communications, vol. 39, no. 1, 58. https://doi.org/10.1186/s40880-019-0403-7

Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma : Consortium for improving survival of lymphoma (CISL) study. / Oh, Sung Yong; Kim, Won Seog; Kim, Jin Seok; Kim, Seok Jin; Yoon, Dok Hyun; Yang, Deok Hwan; Lee, Won Sik; Kim, Hyo Jung; Yhim, Ho Young; Jeong, Seong Hyun; Won, Jong Ho; Lee, Suee; Kong, Jee Hyun; Lim, Sung Nam; Ji, Jun Ho; Kwon, Kyung A.; Lee, Gyeong Won; Lee, Jae Hoon; Lee, Ho Sup; Shin, Ho Jin; Suh, Cheolwon.

In: Cancer Communications, Vol. 39, No. 1, 58, 16.10.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma

T2 - Consortium for improving survival of lymphoma (CISL) study

AU - Oh, Sung Yong

AU - Kim, Won Seog

AU - Kim, Jin Seok

AU - Kim, Seok Jin

AU - Yoon, Dok Hyun

AU - Yang, Deok Hwan

AU - Lee, Won Sik

AU - Kim, Hyo Jung

AU - Yhim, Ho Young

AU - Jeong, Seong Hyun

AU - Won, Jong Ho

AU - Lee, Suee

AU - Kong, Jee Hyun

AU - Lim, Sung Nam

AU - Ji, Jun Ho

AU - Kwon, Kyung A.

AU - Lee, Gyeong Won

AU - Lee, Jae Hoon

AU - Lee, Ho Sup

AU - Shin, Ho Jin

AU - Suh, Cheolwon

PY - 2019/10/16

Y1 - 2019/10/16

N2 - Background: The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending the period of remission in MZL patients remains an essential goal. This multicenter, single-arm, open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP (rituximab, cyclophosphamide, vincristine, and prednisolone). The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further investigation. Methods: Prior to rituximab-maintenance therapy, patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV MZL. Rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), and vincristine (1.4 mg/m2; maximum 2 mg) were administered via an intravenous infusion on day 1 of each 3-week cycle, while oral prednisolone (100 mg) was given on days 1-5 of each 3-week cycle. The patients who achieved complete response (CR), partial response (PR), or stable disease (SD) to R-CVP treatment, were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m2 every 8 weeks for up to 12 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and treatment safety. Results: 47 patients were enrolled, of whom, 45 (96%) received rituximab-maintenance treatment. Fifteen (33%) patients had nodal MZL. Following R-CVP first-line therapy, 20 (44%), 22 (49%), and 3 (7%) patients achieved CR, PR, and SD, respectively. After a median follow-up of 38.2 months, their observed 3-year PFS rate was 81%. During the rituximab-maintenance, 6 PR and 1 SD patients achieved CR following the administration of R-CVP. Elevated LDH and the presence of B symptoms were found to be significant prognostic factors for PFS (P = 0.003) and demonstrated a 3-year OS rate of 90%. Rituximab-maintenance therapy was well tolerated, and the common treatment-emergent adverse events were sensory neuropathy (18%), myalgia (13%), fatigue (9%), and neutropenia (9%). Conclusion: Rituximab-maintenance therapy following first-line R-CVP demonstrated good PFS in patients with stage III-IV MZL, in addition to a favorable toxicity profile. Trial registration clinicaltrials.gov: NCT01213095

AB - Background: The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending the period of remission in MZL patients remains an essential goal. This multicenter, single-arm, open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP (rituximab, cyclophosphamide, vincristine, and prednisolone). The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further investigation. Methods: Prior to rituximab-maintenance therapy, patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV MZL. Rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), and vincristine (1.4 mg/m2; maximum 2 mg) were administered via an intravenous infusion on day 1 of each 3-week cycle, while oral prednisolone (100 mg) was given on days 1-5 of each 3-week cycle. The patients who achieved complete response (CR), partial response (PR), or stable disease (SD) to R-CVP treatment, were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m2 every 8 weeks for up to 12 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and treatment safety. Results: 47 patients were enrolled, of whom, 45 (96%) received rituximab-maintenance treatment. Fifteen (33%) patients had nodal MZL. Following R-CVP first-line therapy, 20 (44%), 22 (49%), and 3 (7%) patients achieved CR, PR, and SD, respectively. After a median follow-up of 38.2 months, their observed 3-year PFS rate was 81%. During the rituximab-maintenance, 6 PR and 1 SD patients achieved CR following the administration of R-CVP. Elevated LDH and the presence of B symptoms were found to be significant prognostic factors for PFS (P = 0.003) and demonstrated a 3-year OS rate of 90%. Rituximab-maintenance therapy was well tolerated, and the common treatment-emergent adverse events were sensory neuropathy (18%), myalgia (13%), fatigue (9%), and neutropenia (9%). Conclusion: Rituximab-maintenance therapy following first-line R-CVP demonstrated good PFS in patients with stage III-IV MZL, in addition to a favorable toxicity profile. Trial registration clinicaltrials.gov: NCT01213095

UR - http://www.scopus.com/inward/record.url?scp=85073425331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073425331&partnerID=8YFLogxK

U2 - 10.1186/s40880-019-0403-7

DO - 10.1186/s40880-019-0403-7

M3 - Article

C2 - 31619290

AN - SCOPUS:85073425331

VL - 39

JO - Cancer Communications

JF - Cancer Communications

SN - 1000-467X

IS - 1

M1 - 58

ER -